bell
The current prices are delayed by 15 mins, login to check live prices.
Glenmark Life Sciences Ltd share price logo

Glenmark Life Sciences Ltd

(GLS)

₹1036.351.29%

as on 04:01PM, 12 Dec 2024

Overview
News
Financials
Q2 2024 Results
Technicals

Glenmark Life Sciences Ltd Analyst Rating

based on 5 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 5 analysts offering long term price targets for Glenmark Life Sciences Ltd. An average target of ₹1138.6

Source: S&P Global Market Intelligence

Glenmark Life Sciences Ltd Share analysis

Glenmark Life Sciences Ltd price forecast by 5 analysts

Upside of8.45%

High

₹1295

Target

₹1138.60

Low

₹1015

Glenmark Life Sciences Ltd target price ₹1138.6, a slight upside of 8.45% compared to current price of ₹1036.35. According to 5 analysts rating.

Source: S&P Global Market Intelligence

Glenmark Life Sciences Ltd Performance

  • Day's Low

    Day's High

    ₹1,015.8
    ₹1,059.95
  • 52 Week's Low

    52 Week's High

    ₹627.15
    ₹1,335.1
1 Month Return-4.49 %
3 Month Return-19.61 %
1 Year Return+ 64.22 %
Previous Close₹1,049.85
Open₹1,049.85
Volume80.15K
Upper Circuit-
Lower Circuit-
Market Cap₹12,864.11Cr

Glenmark Life Sciences Ltd Key Statistics

P/E Ratio0
PEG Ratio0
Market Cap₹12,864.11 Cr
P/B Ratio4.07
EPS0
Dividend Yield0
SectorPharmaceuticals
ROE21.07

Glenmark Life Sciences Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
BUY₹12,864.11 Cr8.05%0.51NANA
NA₹226.88 Cr89%0.51NANA
NA₹352.64 Cr68.63%0.68₹6 Cr₹305 Cr
NA₹658.33 Cr447.24%0.54₹23 Cr₹164 Cr
NA₹302.57 Cr463.22%0.53NANA

About Glenmark Life Sciences Ltd

Glenmark Life Sciences Private Limited (formerly Zorg Laboratories Private Limited) was incorporated as a private limited company on 23 June 2011. It was acquired by Glenmark Pharmaceuticals Limited in July 2018, and was converted to a public company in August 2018. Operating as a wholly-owned subsidiary of Glenmark Pharmaceuticals, the company is engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs). The company has Research and Development (R&D) facilities in Mahape, Ankleshwar, and Dahej, while its manufacturing facilities are located in Ankleshwar, Dahej, Mohol, and Kurkumbh. On 13 August 2018, Glenmark Life Sciences allotted 4,500,090 equity shares of Rs. 10 each upon conversion of a loan given to the Director, and 15,000,000 shares to its parent company Glenmark Pharmaceuticals under preferential allotment. The company recently concluded its IPO, of a total of 21,022,222 equity shares, raising Rs. 15136 million. All of the outstanding purchase consideration was repaid from the proceeds of the IPO, and the company’s equity shares are now listed on both the BSE and NSE.

Share Price: ₹1036.35 per share as on 12 Dec, 2024 04:01 PM
Market Capitalisation: ₹12,864.11Cr as of today
Listing date: 06 Aug, 2021
Chairperson Name: Glenn Saldanha
OrganisationGlenmark Life Sciences Ltd
Headquarters
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Glenmark Life Sciences Ltd

  • Glenmark Life Faces Profit Decline Amid Facility Closure - 25 Oct, 2024

    Glenmark Life Sciences reported a 20% year-on-year decline in net profit to ₹95.32 crore for Q2 FY25, primarily due to the temporary closure of its Gujarat manufacturing facility. The stock fell nearly 10% following the announcement, reflecting investor concerns over the impact on revenue and operations.
  • Glenmark Life Sciences Reports Q2 FY25 Financial Decline - 24 Oct, 2024

    Glenmark Life Sciences reported a 15% YoY decline in revenue to ₹506.88 crore and a 20% drop in net profit to ₹95.32 crore for Q2 FY25. The company faces challenges in revenue generation and profitability but aims to improve through operational efficiency and product expansion.

Insights on Glenmark Life Sciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 10.76% to 12.98% in Sep 2024 quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 4.82% to 7.85% in Sep 2024 quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 1.01% to 2.82% in Sep 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 137.9% return, outperforming this stock by 67.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Torrent Pharmaceuticals Ltd has given 64.8% return, outperforming this stock by 0.6%

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 82.85% to 75.00% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, GLS stock has moved down by -19.6%

Glenmark Life Sciences Ltd Financials

Value in ₹ crore
Details2021202220232024
Total Assets₹1,999.10Cr (-)₹2,472.09Cr (↑23.66%)₹2,703.98Cr (↑9.38%)₹2,854.97Cr (↑5.58%)
Total Liabilities₹1,246.35Cr (-)₹417.77Cr (↓66.48%)₹565.77Cr (↑35.43%)₹522.64Cr (↓7.62%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹195.01Cr (-)₹388.11Cr (↑99.02%)₹597.59Cr (↑53.97%)₹306.01Cr (↓48.79%)₹413.52Cr (↑35.13%)

Index Inclusions

BSE Healthcare

₹44,176.87

-0.58 (-256.19%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

BSE Small-Cap

₹57,125.14

-1 (-578.34%)

Glenmark Life Sciences Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
75%
-9.48
Foreign Institutions
7.85%
63.12
Mutual Funds
2.82%
178.19
Retail Investors
12.98%
20.63
Others
1.34%
140.56

Glenmark Life Sciences Ltd Key Indicators

Details20202021202220232024
Return On Equity %127.8460.9129.8322.2821.07

Glenmark Life Sciences Ltd Earnings and Dividends

  • Glenmark Life Sciences Ltd Earnings Results

    Glenmark Life Sciences Ltd’s net profit fell -19.72% since last year same period to ₹95.32Cr in the Q2 2024-2025. On a quarterly growth basis, Glenmark Life Sciences Ltd has generated -14.5% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Glenmark Life Sciences Ltd Dividends October,2023

    In the quarter ending September 2023, Glenmark Life Sciences Ltd has declared dividend of ₹22.50 - translating a dividend yield of 4.20%.

    Read More about Dividends

Glenmark Life Sciences Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Glenmark Life Sciences Ltd is currently in a Bearish trading position according to technical analysis indicators.

FAQs on Glenmark Life Sciences Ltd

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Glenmark Life Sciences Ltd shares.

Glenmark Life Sciences Ltd (GLS) share price today is ₹1036.35

Glenmark Life Sciences Ltd is listed on NSE

Glenmark Life Sciences Ltd is listed on BSE

  • Today’s highest price of Glenmark Life Sciences Ltd is ₹1059.95.
  • Today’s lowest price of Glenmark Life Sciences Ltd is ₹1015.8.

Today’s traded volume of Glenmark Life Sciences Ltd(GLS) is 80.15K.

Today’s market capitalisation of Glenmark Life Sciences Ltd(GLS) is ₹12864.11Cr.

Glenmark Life Sciences Ltd(GLSPrice
52 Week High
₹1335.1
52 Week Low
₹627.15

Glenmark Life Sciences Ltd(GLS) share price is ₹1036.35. It is down -22.38% from its 52 Week High price of ₹1335.1

Glenmark Life Sciences Ltd(GLS) share price is ₹1036.35. It is up 65.25% from its 52 Week Low price of ₹627.15

Glenmark Life Sciences Ltd(GLSReturns
1 Day Returns
-13.5%
1 Month Returns
-4.49%
3 Month Returns
-19.61%
1 Year Returns
64.22%